11 unchanged sentences
Description of Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 .
−Removed: Open Market Sales Agreement, dated March 28, 2023, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Jefferies LLC.
−Removed: Amendment to Amended and Restated Employment Agreement, dated as of March 31, 2023, by and between Corvus Pharmaceuticals, Inc.
−Removed: and Richard A.
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
7 unchanged sentences
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
−Removed: The cover page of Corvus Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the three months ended June 30, 2023, formatted in Inline XBRL (contained in Exhibit 101).
−Removed: Indicates management contract or compensatory plan.
+Added: The cover page of Corvus Pharmaceuticals, Inc.’s Quarterly Report on Form 10-Q for the three months ended September 30, 2023, formatted in Inline XBRL (contained in Exhibit 101).
The certification attached as Exhibit 32.1 that accompanies this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Corvus Pharmaceuticals, Inc.
2 unchanged sentences
CORVUS PHARMACEUTICALS, INC.
−Removed: August 8, 2023
+Added: November 7, 2023
President, Chief Executive Officer and Director
(Principal Executive Officer)
−Removed: August 8, 2023
+Added: November 7, 2023
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.